INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 137 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2019. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $649,000 | -39.6% | 18,921 | -86.9% | 0.03% | -40.7% |
| Q3 2019 | $1,075,000 | +149.4% | 143,921 | +333.2% | 0.05% | +125.0% |
| Q2 2019 | $431,000 | +31.8% | 33,221 | +23.9% | 0.02% | +20.0% |
| Q1 2019 | $327,000 | -33.3% | 26,818 | -37.6% | 0.02% | -37.5% |
| Q4 2018 | $490,000 | -42.2% | 42,996 | +10.0% | 0.03% | -17.9% |
| Q3 2018 | $848,000 | -19.7% | 39,096 | -34.6% | 0.04% | -9.3% |
| Q2 2018 | $1,056,000 | -10.0% | 59,796 | -26.2% | 0.04% | -17.3% |
| Q4 2017 | $1,173,000 | -47.3% | 81,010 | -42.6% | 0.05% | -54.4% |
| Q3 2017 | $2,227,000 | +246.9% | 141,157 | +173.1% | 0.11% | +235.3% |
| Q2 2017 | $642,000 | -60.9% | 51,693 | -48.9% | 0.03% | -55.3% |
| Q1 2017 | $1,644,000 | +9.7% | 101,200 | +1.9% | 0.08% | -14.6% |
| Q4 2016 | $1,498,000 | – | 99,300 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |